Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 3,970 Shares
by Teresa Graham · The Cerbat GemAvalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) insider Mittie Doyle sold 3,970 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $18.01, for a total transaction of $71,499.70. Following the completion of the sale, the insider directly owned 3,622 shares of the company’s stock, valued at $65,232.22. This represents a 52.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mittie Doyle also recently made the following trade(s):
- On Wednesday, April 1st, Mittie Doyle sold 679 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.00, for a total transaction of $10,864.00.
- On Monday, March 16th, Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80.
Avalo Therapeutics Trading Down 9.5%
Shares of AVTX opened at $14.41 on Thursday. Avalo Therapeutics, Inc. has a 12-month low of $3.39 and a 12-month high of $20.72. The firm has a 50-day moving average price of $15.54 and a 200 day moving average price of $16.09. The firm has a market capitalization of $328.40 million, a P/E ratio of -2.51 and a beta of 0.93.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of ($0.21) million. Equities research analysts predict that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. BIT Capital GmbH acquired a new position in Avalo Therapeutics in the third quarter valued at about $25,000. PFS Partners LLC lifted its position in Avalo Therapeutics by 100.0% in the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after buying an additional 1,000 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics in the second quarter valued at about $56,000. Dimensional Fund Advisors LP acquired a new position in Avalo Therapeutics in the third quarter valued at about $143,000. Finally, Jump Financial LLC acquired a new position in Avalo Therapeutics in the fourth quarter valued at about $238,000. Institutional investors and hedge funds own 87.06% of the company’s stock.
Analyst Ratings Changes
AVTX has been the subject of a number of analyst reports. Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Guggenheim assumed coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They issued a “buy” rating and a $50.00 target price on the stock. Finally, Citizens Jmp assumed coverage on shares of Avalo Therapeutics in a research report on Monday. They issued an “outperform” rating and a $52.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.20.
Get Our Latest Analysis on Avalo Therapeutics
Avalo Therapeutics Company Profile
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.